Photo of Audrey Allen

Audrey Allen

Subscribe to Audrey Allen's Posts

Audrey focuses her legal practice on resolving mass toxic tort and product liability litigation for clients.

As a member of the firm’s Toxic Tort team, Audrey concentrates her practice on the defense of oil refineries and premises defendants involved in asbestos exposure claims nationwide. She also focuses on products liability and complex commercial litigation matters. Audrey works closely with clients throughout all stages of litigation, including drafting motions and pleadings, completing discovery, taking and defending depositions, arguing motions and negotiating settlements. She is also experienced in analyzing and summarizing medical records and conducting research to retain experts.

Contact:Read more about Audrey Allen
FDA

In April, the U.S. Food and Drug Administration (FDA) released the results of its 2023 sampling assignment, testing for asbestos in talc-containing products. The results confirmed the absence of asbestos in all 50 samples tested, marking the third consecutive year of asbestos-free talc products in the United States. While this news is reassuring for industry participants, the legal landscape remains complex due to ongoing litigation. This article explores the legal implications, potential risks, and regulatory changes related to asbestos detection in cosmetic talc products.

New York’s Court of Appeals recently reversed a $16,500,000 asbestos jury verdict in a case brought by decedent Florence Nemeth and her husband, who alleged that Mrs. Nemeth’s cancer was caused by her use of Desert Flower Talcum Powder. In Nemeth v. Brenntag North America, et al., 2022 WL 1217464 (Ct. App. NY Apr. 26, 2022), the state’s highest court overturned the decision on the grounds that the plaintiff’s experts failed to present sufficient evidence to prove that the talc-based cosmetic powder caused decedent’s peritoneal mesothelioma.